AbbVie (ABBV - $53.10) Chief executive Rick Gonzalez told
analysts on the fourth-quarter earnings call that management expects
global Humira sales this year will continue growing at a (low) double-digit
pace, excluding the impact of foreign exchange. The pursuit of additional
indications currently in late stage clinical trials, such as Uveitis (inflammation of the eye and the third
leading-cause of blindness), is expected to augment growth too.
Humira –
like Johnson & Johnson's (JNJ) Remicade
– is a manufactured monoclonal antibody that treats autoimmune diseases by
interfering with (blocking) tumor necrosis factor (TNF), an inflammatory
protein over-expressed in a wide range of progressive inflammatory disorders
that can result in permanent tissue and joint damage over time.
Could Humira lose share to biosimilars? Read more at The Motley Fool: AbbVie's
Humira Still a Growth Engine
1 comment:
There are drugs in the pipe for RA that are not dangerous like these TNF types. Will doctors write prescriptions for enbrel, humira, and remicade knowing that non TNF inhibitors will do as good a job without the risk of TNF inhibitors?
Post a Comment